PURETECH HEALTH PLC LS 1
Research PURETECH HEALTH PLC LS 1 (0VQ) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- Ticker0VQ
- ExchangeF
- CountryUnited States
- CurrencyEUR
- Financial periodFY2025
- RevenueUSD 4.66M
- Revenue growth-3.5%
- Net income-USD 110.08M
- Free cash flow-USD 85.14M
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.66M | -USD 110.08M | -USD 85.14M | n/a | -0.46 | USD 252.47M | n/a | USD 312.07M |
| FY2024 | USD 4.83M | USD 27.78M | -USD 134.38M | n/a | 0.21 | USD 280.64M | n/a | USD 414.71M |
| FY2023 | USD 3.33M | -USD 66.63M | -USD 105.99M | n/a | -0.24 | USD 191.08M | USD 0 | USD 458.23M |
| FY2022 | USD 15.62M | -USD 37.07M | -USD 180.97M | n/a | -0.18 | USD 149.87M | USD 15.40M | USD 547.59M |
| FY2021 | USD 17.39M | -USD 62.71M | -USD 163.85M | n/a | -0.21 | USD 465.71M | USD 15.12M | USD 584.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | n/a | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About PURETECH HEALTH PLC LS 1
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody.
Related stock research
Other related stocks
Frequently asked questions
What does PURETECH HEALTH PLC LS 1 do?
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody.